Table 4.
Concordance of Patient Recall with Medical Chart Data in Reporting Use of the 10 Most Commonly Prescribed Chemotherapeutic Agents for Breast Cancer Treatment, Shanghai, China, 2002-2006.
| Chemotherapeutic Agent | % that reported use of drug on PQa | % of MCb that reported use of drug | Agreement (%) | Kappa |
|---|---|---|---|---|
| Fluorouracil | 71.0 | 68.8 | 84.9 | 0.64 |
| Cyclophosphamide | 70.1 | 59.7 | 82.5 | 0.62 |
| Epirubicin | 52.4 | 46.0 | 81.7 | 0.64 |
| Methotrexate | 19.6 | 16.1 | 92.1 | 0.73 |
| Calcium folinate | 14.7 | 14.4 | 85.4 | 0.41 |
| Pirarubicin | 12.4 | 8.8 | 90.8 | 0.51 |
| Novel drugs c | 9.5 | 4.7 | 95.7 | 0.63 |
| Vinorelbine | 8.1 | 6.9 | 96.7 | 0.76 |
| Docetaxel | 4.2 | 2.4 | 97.8 | 0.65 |
| Paclitaxel | 3.4 | 2.5 | 98.0 | 0.65 |
a PQ: Patient questionnaire.
b MC: Medical chart.
c Novel drugs include the following list of pharmaceuticals, all of which were approved in China for use in breast cancer patients in 2002, the year both surveys were conducted: altretamine, oxaliplatin, gemcitabine, trastuzumab, ifosfamide, temozolomide, and Aredia.